REFERENCES:

1. Sachdev, P. S., Blacker, D., Blazer, D. G., Ganguli, M., Jeste, D. V., Paulsen, J. S., & Petersen, R. C. (2014). Classifying neurocognitive disorders: The DSM-5 approach. Nature Reviews Neurology, 10(11), 634–642. https://doi.org/10.1038/nrneurol.2014.181
2. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). https://doi.org/10.1176/appi.books.9780890425596
3. Prince, M., Wimo, A., Guerchet, M., Ali, G. C., Wu, Y. T., & Prina, M. (2015). World Alzheimer Report 2015: The global impact of dementia: An analysis of prevalence, incidence, cost and trends. Alzheimer’s Disease International.
4. Snyder, H. R., Miyake, A., & Hankin, B. L. (2015). Advancing understanding of executive function impairments and psychopathology: Bridging the gap between clinical and cognitive approaches. Frontiers in Psychology, 6, Article 328. https://doi.org/10.3389/fpsyg.2015.00328
5. Thapar, A., & Cooper, M. (2016). Attention deficit hyperactivity disorder. The Lancet, 387(10024), 1240–1250. https://doi.org/10.1016/S0140-6736(15)00238-X
6. Kalia, L. V., & Lang, A. E. (2015). Parkinson’s disease. The Lancet, 386(9996), 896–912. https://doi.org/10.1016/S0140-6736(14)61393-3
7. Modabbernia, A., Velthorst, E., & Reichenberg, A. (2017). Environmental risk factors for autism: An evidence-based review of systematic reviews and meta-analyses. Molecular Autism, 8, Article 13. https://doi.org/10.1186/s13229-017-0121-4
8. Grandjean, P., & Landrigan, P. J. (2014). Neurobehavioural effects of developmental toxicity. The Lancet Neurology, 13(3), 330–338. https://doi.org/10.1016/S1474-4422(13)70278-3
9. Jakovcevski, M., & Akbarian, S. (2012). Epigenetic mechanisms in neurological disease. Nature Medicine, 18(8), 1194–1204. https://doi.org/10.1038/nm.2879
10. Lister, R., Mukamel, E. A., Nery, J. R., Urich, M., Puddifoot, C. A., Johnson, N. D., … & Ecker, J. R. (2013). Global epigenomic reconfiguration during mammalian brain development. Science, 341(6146), 1237905. https://doi.org/10.1126/science.1237905
11. Day, J. J., & Sweatt, J. D. (2011). Epigenetic mechanisms in cognition. Neuron, 70(5), 813–829. https://doi.org/10.1016/j.neuron.2011.05.019
12. Cavalli, G., & Heard, E. (2019). Advances in epigenetics link genetics to the environment and disease. Nature, 571(7766), 489–499. https://doi.org/10.1038/s41586-019-1411-0
13. Sen, P., Shah, P. P., Nativio, R., & Berger, S. L. (2016). Epigenetic mechanisms of longevity and aging. Cell, 166(4), 822–839. https://doi.org/10.1016/j.cell.2016.07.050
14. Nagarajan, R., Hogart, A., Gwye, Y., Martin, M. R., & LaSalle, J. M. (2006). Reduced MeCP2 expression is frequent in autism frontal cortex and correlates with aberrant MECP2 promoter methylation. Epigenetics, 1(4), 172–182. https://doi.org/10.4161/epi.1.4.3514
15. Siu, M. T., Butcher, D. T., Turinsky, A. L., Cytrynbaum, C., Stavropoulos, D. J., Walker, S., … & Weksberg, R. (2019). Functional DNA methylation signatures for autism spectrum disorder genomic risk loci: 16p11.2 deletions and CHD8 variants. Clinical Epigenetics, 11(1), Article 103. https://doi.org/10.1186/s13148-019-0705-2
16. Ladd-Acosta, C., Hansen, K. D., Briem, E., Fallin, M. D., Kaufmann, W. E., & Feinberg, A. P. (2014). Common DNA methylation alterations in multiple brain regions in autism. Molecular Psychiatry, 19(8), 862–871. https://doi.org/10.1038/mp.2013.114
17. Wong, C. C., Smith, R. G., Hannon, E., Ramaswami, G., Parikshak, N. N., Assary, E., … & Mill, J. (2019). Genome-wide DNA methylation profiling identifies convergent molecular signatures associated with idiopathic and syndromic autism in post-mortem human brain tissue. Human Molecular Genetics, 28(13), 2201–2211. https://doi.org/10.1093/hmg/ddz052
18. LaSalle, J. M. (2023). Epigenomic signatures reveal mechanistic clues and predictive markers for autism spectrum disorder. Molecular Psychiatry, 28(5), 1890–1901. https://doi.org/10.1038/s41380-023-02012-6
19. Hannon, E., Schendel, D., Ladd-Acosta, C., Grove, J., Hansen, C. S., Andrews, S. V., … & Mill, J. (2018). Elevated polygenic burden for autism is associated with differential DNA methylation at birth. Genome Medicine, 10(1), Article 19. https://doi.org/10.1186/s13073-018-0527-2
20. Mordaunt, C. E., Jianu, J. M., Laufer, B. I., Zhu, Y., Hwang, H., Dunaway, K. W., … & LaSalle, J. M. (2020). Cord blood DNA methylome in newborns later diagnosed with autism spectrum disorder reflects early dysregulation of neurodevelopmental and X-linked genes. Genome Medicine, 12(1), Article 88. https://doi.org/10.1186/s13073-020-00785-x
21. Qureshi, I. A., & Mehler, M. F. (2010). Epigenetic mechanisms underlying human epileptic disorders and the process of epileptogenesis. Neurobiology of Disease, 39(1), 53–60. https://doi.org/10.1016/j.nbd.2010.02.005
22. Guan, J. S., Haggarty, S. J., Giacometti, E., Dannenberg, J. H., Joseph, N., Gao, J., … & Tsai, L. H. (2009). HDAC2 negatively regulates memory formation and synaptic plasticity. Nature, 459(7243), 55–60. https://doi.org/10.1038/nature07927
23. Schaefer, A., Sampath, S. C., Intrator, A., Min, A., Gertler, T. S., Surmeier, D. J., Tarakhovsky, A., & Greengard, P. (2009). Control of cognition and adaptive behavior by the GLP/G9a epigenetic suppressor complex. Neuron, 64(5), 678–691. https://doi.org/10.1016/j.neuron.2009.11.019
24. Abu-Elneel, K., Liu, T., Gazzaniga, F. S., Nishimura, Y., Wall, D. P., Geschwind, D. H., … & Kosik, K. S. (2008). Heterogeneous dysregulation of microRNAs across the autism spectrum. Neurogenetics, 9(3), 153–161. https://doi.org/10.1007/s10048-008-0127-4
25. Schepici, G., Cavalli, E., Bramanti, P., & Mazzon, E. (2019). Autism spectrum disorder and miRNA: An overview of experimental models. Brain Sciences, 9(10), Article 265. https://doi.org/10.3390/brainsci9100265
26. Li, J., Xu, X., Liu, J., Zhang, S., Tan, X., Li, Z., Liu, S., & Wang, Z. (2022). Decoding microRNAs in autism spectrum disorder. Molecular Therapy: Nucleic Acids, 30, 535–546. https://doi.org/10.1016/j.omtn.2022.10.015
27. Wiers, C. E., Lohoff, F. W., Lee, J., Muench, C., Freeman, C., Zehra, A., … & Volkow, N. D. (2018). Methylation of the dopamine transporter gene in blood is associated with striatal dopamine transporter availability in ADHD: A preliminary study. European Journal of Neuroscience, 48(3), 1884–1895. https://doi.org/10.1111/ejn.14032
28. Dadds, M. R., Schollar-Root, O., Lenroot, R., Moul, C., & Hawes, D. J. (2016). Epigenetic regulation of the DRD4 gene and dimensions of attention-deficit/hyperactivity disorder in children. European Child & Adolescent Psychiatry, 25(10), 1081–1089. https://doi.org/10.1007/s00787-016-0830-6
29. Miyake, K., Miyashita, C., Ikeda-Araki, A., Miura, R., Itoh, S., Yamazaki, K., … & Kishi, R. (2021). DNA methylation of GFI1 as a mediator of the association between prenatal smoking exposure and ADHD symptoms at 6 years: The Hokkaido Study on Environment and Children’s Health. Clinical Epigenetics, 13(1), Article 74. https://doi.org/10.1186/s13148-021-01053-x
30. Mooney, M. A., Ryabinin, P., Wilmot, B., Bhatt, P., Mill, J., & Nigg, J. T. (2020). Large epigenome-wide association study of childhood ADHD identifies peripheral DNA methylation associated with disease and polygenic risk burden. Translational Psychiatry, 10(1), Article 8. https://doi.org/10.1038/s41398-020-0705-1
31. Baccarelli, A., & Ghosh, S. (2012). Environmental exposures, epigenetics and cardiovascular disease. Current Opinion in Clinical Nutrition and Metabolic Care, 15(4), 323–329. https://doi.org/10.1097/MCO.0b013e328354bf5c
32. De Gregorio, R., Pulcrano, S., De Sanctis, C., Volpicelli, F., Guatteo, E., Von Oerthel, L., Smidt, M. P., & Bellenchi, G. C. (2018). miR-34b/c regulates Wnt1 and enhances mesencephalic dopaminergic neuron differentiation. Stem Cell Reports, 10(4), 1237–1250. https://doi.org/10.1016/j.stemcr.2018.02.006
33. Wu, C., Zhang, X., Chen, P., Ruan, X., Liu, W., Li, Y., Wang, Y., & Peng, X. (2019). MicroRNA-129 modulates neuronal migration by targeting Fmr1 in the developing mouse cortex. Cell Death & Disease, 10(4), Article 287. https://doi.org/10.1038/s41419-019-1516-x
34. Sánchez-Mora, C., Soler Artigas, M., Garcia-Martínez, I., Pagerols, M., Rovira, P., Richarte, V., Corrales, M., Corominas, M., Bosch, R., Casas, M., Ramos-Quiroga, J. A., & Ribasés, M. (2019). Epigenetic signature for attention-deficit/hyperactivity disorder: Identification of miR-26b-5p, miR-185-5p, and miR-191-5p as potential biomarkers in peripheral blood mononuclear cells. Neuropsychopharmacology, 44(5), 890–897. https://doi.org/10.1038/s41386-018-0280-2
35. Shastri, G. G., Sudre, G., Ahn, K., Jung, B., Kolachana, B., Auluck, P. K., Elnitski, L., & Shaw, P. (2024). Examining epigenetic aging in the post-mortem brain in attention deficit hyperactivity disorder. Frontiers in Genetics, 15, Article 1480761. https://doi.org/10.3389/fgene.2024.1480761
36. Mastroeni, D., Grover, A., Delvaux, E., Whiteside, C., Coleman, P. D., & Rogers, J. (2011). Epigenetic mechanisms in Alzheimer’s disease. Neurobiology of Aging, 32(7), 1161–1180. https://doi.org/10.1016/j.neurobiolaging.2010.11.010
37. Lunnon, K., Smith, R., Hannon, E., De Jager, P. L., Srivastava, G., Volta, M., Troakes, C., Al-Sarraj, S., Burrage, J., Macdonald, R., Condliffe, D., Harries, L. W., Katsel, P., Haroutunian, V., Kaminsky, Z., Joachim, C., Powell, J., Lovestone, S., Bennett, D. A., Schalkwyk, L. C., … Mill, J. (2014). Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer’s disease. Nature Neuroscience, 17(9), 1164–1170. https://doi.org/10.1038/nn.3782
38. De Plano, L. M., Saitta, A., Oddo, S., & Caccamo, A. (2024). Epigenetic changes in Alzheimer’s disease: DNA methylation and histone modification. Cells, 13(8), Article 719. https://doi.org/10.3390/cells13080719
39. Panitch, R., Sahelijo, N., Hu, J., Nho, K., Bennett, D. A., Lunetta, K. L., … & Jun, G. R. (2024). APOE genotype-specific methylation patterns are linked to Alzheimer disease pathology and estrogen response. Translational Psychiatry, 14(1), Article 129. https://doi.org/10.1038/s41398-024-02839-x
40. Kobayashi, N., Shinagawa, S., Nagata, T., Shimada, K., Shibata, N., Ohnuma, T., … & Kondo, K. (2016). Usefulness of DNA methylation levels in COASY and SPINT1 gene promoter regions as biomarkers in diagnosis of Alzheimer’s disease and amnestic mild cognitive impairment. PLOS ONE, 11(12), Article e0168816. https://doi.org/10.1371/journal.pone.0168816
41. Nagata, T., Kobayashi, N., Ishii, J., Shinagawa, S., Nakayama, R., Shibata, N., Kuerban, B., Ohnuma, T., Kondo, K., Arai, H., Yamada, H., & Nakayama, K. (2015). Association between DNA methylation of the BDNF promoter region and clinical presentation in Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders Extra, 5(1), 64–73. https://doi.org/10.1159/000375370
42. Gräff, J., Rei, D., Guan, J. S., Wang, W. Y., Seo, J., Hennig, K. M., Nieland, T. J., Fass, D. M., Kao, P. F., Kahn, M., Su, S. C., Samiei, A., Joseph, N., Haggarty, S. J., Delalle, I., & Tsai, L. H. (2012). An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature, 483(7388), 222–226. https://doi.org/10.1038/nature10849
43. McQuown, S. C., & Wood, M. A. (2011). HDAC3 and the molecular brake pad hypothesis. Neurobiology of Learning and Memory, 96(1), 27–34. https://doi.org/10.1016/j.nlm.2011.04.005
44. Gräff, J., & Tsai, L. H. (2013). Histone acetylation: Molecular mnemonics on the chromatin. Nature Reviews Neuroscience, 14(2), 97–111. https://doi.org/10.1038/nrn3427
45. Hébert, S. S., Horré, K., Nicolaï, L., Papadopoulou, A. S., Mandemakers, W., Silahtaroglu, A. N., Kauppinen, S., Delacourte, A., & De Strooper, B. (2008). Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates with increased BACE1/beta-secretase expression. Proceedings of the National Academy of Sciences of the United States of America, 105(17), 6415–6420. https://doi.org/10.1073/pnas.0710263105
46. Wang, W. X., Rajeev, B. W., Stromberg, A. J., Ren, N., Tang, G., Huang, Q., Rigoutsos, I., & Nelson, P. T. (2008). The expression of microRNA miR-107 decreases early in Alzheimer’s disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. The Journal of Neuroscience, 28(5), 1213–1223. https://doi.org/10.1523/JNEUROSCI.5065-07.2008
47. Delay, C., Mandemakers, W., & Hébert, S. S. (2012). MicroRNAs in Alzheimer’s disease. Neurobiology of Disease, 46(2), 285–290. https://doi.org/10.1016/j.nbd.2012.01.003
48. Jowaed, A., Schmitt, I., Kaut, O., & Wüllner, U. (2010). Methylation regulates alpha-synuclein expression and is decreased in Parkinson’s disease patients’ brains. Journal of Neuroscience, 30(18), 6355–6359. https://doi.org/10.1523/JNEUROSCI.6119-09.2010
49. Masliah, E., Dumaop, W., Galasko, D., & Desplats, P. (2013). Distinctive patterns of DNA methylation associated with Parkinson disease: Identification of concordant epigenetic changes in brain and peripheral blood leukocytes. Epigenetics, 8(10), 1030–1038. https://doi.org/10.4161/epi.25865
50. Park, G., Tan, J., Garcia, G., Kang, Y., Salvesen, G., & Zhang, Z. (2016). Regulation of histone acetylation by autophagy in Parkinson disease. The Journal of Biological Chemistry, 291(7), 3531–3540. https://doi.org/10.1074/jbc.M115.675488
51. Cardo, L. F., Coto, E., de Mena, L., Ribacoba, R., Moris, G., Menéndez, M., & Alvarez, V. (2013). Profile of microRNAs in the plasma of Parkinson’s disease patients and healthy controls. Journal of Neurology, 260(5), 1420–1422. https://doi.org/10.1007/s00415-013-6900-3
52. Klokkaris, A., & Migdalska-Richards, A. (2024). An overview of epigenetic changes in the Parkinson’s disease brain. International Journal of Molecular Sciences, 25(11), Article 6168. https://doi.org/10.3390/ijms25116168
53. Rasheed, M., Liang, J., Wang, C., Deng, Y., & Chen, Z. (2021). Epigenetic regulation of neuroinflammation in Parkinson’s disease. International Journal of Molecular Sciences, 22(9), Article 4956. https://doi.org/10.3390/ijms22094956
54. Shukla, S., & Tekwani, B. L. (2020). Histone deacetylases inhibitors in neurodegenerative diseases, neuroprotection and neuronal differentiation. Frontiers in Pharmacology, 11, Article 537. https://doi.org/10.3389/fphar.2020.00537
55. Han, B., Gu, X., Wang, M., Wang, H., Sun, N., Yang, X., & Zhang, Q. (2024). Design, synthesis and neuroprotective biological evaluation of novel HDAC6 inhibitors incorporating benzothiadiazinyl systems as cap groups. Chemical Biology & Drug Design, 103(5), Article e14556. https://doi.org/10.1111/cbdd.14556
56. Schneider, T., & Przewłocki, R. (2005). Behavioral alterations in rats prenatally exposed to valproic acid: Animal model of autism. Neuropsychopharmacology, 30(1), 80–89. https://doi.org/10.1038/sj.npp.1300582
57. Mony, T. J., Lee, J. W., Dreyfus, C., DiCicco-Bloom, E., & Lee, H. J. (2016). Valproic acid exposure during early postnatal gliogenesis leads to autistic-like behaviors in rats. Clinical Psychopharmacology and Neuroscience, 14(4), 338–344. https://doi.org/10.9758/cpn.2016.14.4.338
58. Bath, K. G., & Pimentel, T. (2017). Effect of early postnatal exposure to valproate on neurobehavioral development and regional BDNF expression in two strains of mice. Epilepsy & Behavior, 70(Pt A), 110–117. https://doi.org/10.1016/j.yebeh.2017.02.026
59. Kratsman, N., Getselter, D., & Elliott, E. (2016). Sodium butyrate attenuates social behavior deficits and modifies the transcription of inhibitory/excitatory genes in the frontal cortex of an autism model. Neuropharmacology, 102, 136–145. https://doi.org/10.1016/j.neuropharm.2015.11.003
60. Cristiano, C., Hoxha, E., Lippiello, P., Balbo, I., Russo, R., Tempia, F., & Miniaci, M. C. (2022). Maternal treatment with sodium butyrate reduces the development of autism-like traits in mice offspring. Biomedicine & Pharmacotherapy, 156, Article 113870. https://doi.org/10.1016/j.biopha.2022.113870
61. Scharf, S. H., Jaeschke, G., Wettstein, J. G., & Lindemann, L. (2015). Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome. Current Opinion in Pharmacology, 20, 124–134. https://doi.org/10.1016/j.coph.2014.11.004
62. Frye, R. E., Slattery, J., Delhey, L., Furgerson, B., Strickland, T., Tippett, M., McGinnis, A., & Quadros, E. V. (2018). Folinic acid improves verbal communication in children with autism and language impairment: A randomized double-blind placebo-controlled trial. Molecular Psychiatry, 23(2), 247–256. https://doi.org/10.1038/mp.2016.168
63. Gregory, S. G., Connelly, J. J., Towers, A. J., Johnson, J., Biscocho, D., Markunas, C. A., Lintas, C., Confalonieri, F. P., Crawley, J. N., Sethna, S., Wagenbach, M. C., Cuccaro, M. L., Abramson, R. K., Wright, H. H., Gurrieri, F., Persico, A. M., & Pericak-Vance, M. A. (2009). Genomic and epigenetic evidence for oxytocin receptor deficiency in autism. BMC Medicine, 7(1), Article 62. https://doi.org/10.1186/1741-7015-7-62
64. Strati, F., Cavalieri, D., Albanese, D., De Felice, C., Donati, C., Hayek, J., Jousson, O., Leoncini, S., Renzi, D., Calabrò, A., & De Filippo, C. (2017). New evidences on the altered gut microbiota in autism spectrum disorders. Microbiome, 5(1), Article 24. https://doi.org/10.1186/s40168-017-0242-1
65. Liu, F., Li, J., Wu, F., Zheng, H., Peng, Q., & Zhou, H. (2019). Altered composition and function of intestinal microbiota in autism spectrum disorders: A systematic review. Translational Psychiatry, 9(1), Article 43. https://doi.org/10.1038/s41398-019-0389-6
66. Iglesias-Vázquez, L., Van Ginkel Riba, G., Arija, V., & Canals, J. (2020). Composition of gut microbiota in children with autism spectrum disorder: A systematic review and meta-analysis. Nutrients, 12(3), Article 792. https://doi.org/10.3390/nu12030792
67. Sgritta, M., Dooling, S. W., Buffington, S. A., Momin, E. N., Francis, M. B., Britton, R. A., & Costa-Mattioli, M. (2019). Mechanisms underlying microbial-mediated changes in social behavior in mouse models of autism spectrum disorder. Neuron, 101(2), 246–259.e6. https://doi.org/10.1016/j.neuron.2018.11.018
68. Kong, X.-J., Gao, J., Chen, H., Wang, X., Tang, L., & Zhao, M. (2021). Probiotic and oxytocin combination therapy in patients with autism spectrum disorder: A randomized double-blinded placebo-controlled pilot trial. Nutrients, 13(5), Article 1552. https://doi.org/10.3390/nu13051552
69. He, X., Lim, H. C., & Ninan, I. (2023). Effects of probiotics on autism spectrum disorder in children: A systematic review. Nutrients, 15(6), Article 1415. https://doi.org/10.3390/nu15061415
70. Burokas, A., Arboleya, S., Moloney, R. D., Peterson, V. L., Murphy, K., Clarke, G., Stanton, C., Dinan, T. G., & Cryan, J. F. (2017). Targeting the microbiota-gut-brain axis: Prebiotics have anxiolytic and antidepressant-like effects and reverse the impact of chronic stress in mice. Biological Psychiatry, 82(7), 472–487. https://doi.org/10.1016/j.biopsych.2016.12.031
71. Savignac, H. M., Corona, G., Mills, H., Chen, L., Spencer, J. P., Tzortzis, G., & Burnet, P. W. (2013). Prebiotic feeding elevates central brain derived neurotrophic factor, N-methyl-D-aspartate receptor subunits and D-serine. Neurochemistry International, 63(8), 756–764. https://doi.org/10.1016/j.neuint.2013.10.006
72. Fellows, R., Denizot, J., Stellato, C., Cuomo, A., Jain, P., Stoyanova, E., Balázsi, S., Hajnády, Z., Neubert, A. J., Pappin, D. J., & Varga-Weisz, P. (2018). Microbiota derived short chain fatty acids promote histone crotonylation in the colon through histone deacetylases. Nature Communications, 9(1), Article 105. https://doi.org/10.1038/s41467-017-02651-5
73. Silva, Y. P., Bernardi, A., & Frozza, R. L. (2020). The role of short-chain fatty acids from gut microbiota in gut-brain communication. Frontiers in Endocrinology, 11, Article 25. https://doi.org/10.3389/fendo.2020.00025
74. Kang, D.-W., Adams, J. B., Coleman, D. M., Pollard, E. L., Maldonado, J., McDonough-Means, S., Caporaso, J. G., & Krajmalnik-Brown, R. (2019). Long-term benefit of Microbiota Transfer Therapy on autism symptoms and gut microbiota. Scientific Reports, 9(1), Article 5821. https://doi.org/10.1038/s41598-019-42183-0
75. Zocher, S., Overall, R. W., Lesche, M., Dahl, A., & Kempermann, G. (2021). Environmental enrichment preserves a young DNA methylation landscape in the aged mouse hippocampus. Nature Communications, 12(1), Article 3892. https://doi.org/10.1038/s41467-021-23993-1
76. Griñán-Ferré, C., Puigoriol-Illamola, D., Palomera-Ávalos, V., Pérez-Cáceres, D., Companys-Alemany, J., Camins, A., Ortuño-Sahagún, D., Rodrigo, M. T., & Pallàs, M. (2016). Environmental enrichment modified epigenetic mechanisms in SAMP8 mouse hippocampus by reducing oxidative stress and inflammaging and achieving neuroprotection. Frontiers in Aging Neuroscience, 8, Article 241. https://doi.org/10.3389/fnagi.2016.00241
77. Pang, Y. Y., Lu, R. J., & Chen, P. Y. (2019). Behavioral epigenetics: Perspectives based on experience-dependent epigenetic inheritance. Epigenomes, 3(3), Article 18. https://doi.org/10.3390/epigenomes3030018
78. Surén, P., Roth, C., Bresnahan, M., Haugen, M., Hornig, M., Hirtz, D., Lie, K. K., Lipkin, W. I., Magnus, P., Reichborn-Kjennerud, T., Schjølberg, S., Davey Smith, G., Øyen, A. S., Susser, E., & Stoltenberg, C. (2013). Association between maternal use of folic acid supplements and risk of autism spectrum disorders in children. JAMA, 309(6), 570–577. https://doi.org/10.1001/jama.2012.155912
79. Schmidt, R. J., Iosif, A. M., Guerrero Angel, E., & Ozonoff, S. (2019). Association of maternal prenatal vitamin use with risk for autism spectrum disorder recurrence in young siblings. JAMA Psychiatry, 76(4), 391–398. https://doi.org/10.1001/jamapsychiatry.2018.3901
80. Liu, X., Zou, M., Sun, C., Wu, L., & Chen, W. X. (2022). Prenatal folic acid supplements and offspring’s autism spectrum disorder: A meta-analysis and meta-regression. Journal of Autism and Developmental Disorders, 52(2), 522–539. https://doi.org/10.1007/s10803-021-04951-8
81. Bhandari, R., & Kuhad, A. (2015). Neuropsychopharmacotherapeutic efficacy of curcumin in experimental paradigm of autism spectrum disorders. Life Sciences, 141, 156–169. https://doi.org/10.1016/j.lfs.2015.09.012
82. Zhong, H., Xiao, R., Ruan, R., Liu, H., Li, X., Cai, Y., Zhao, J., & Fan, X. (2020). Neonatal curcumin treatment restores hippocampal neurogenesis and improves autism-related behaviors in a mouse model of autism. Psychopharmacology, 237(12), 3539–3552. https://doi.org/10.1007/s00213-020-05634-5
83. Santos-Terra, J., Deckmann, I., Carello-Collar, G., Nunes, G. D., Bauer-Negrini, G., Schwingel, G. B., Fontes-Dutra, M., Riesgo, R., & Gottfried, C. (2022). Resveratrol prevents cytoarchitectural and interneuronal alterations in the valproic acid rat model of autism. International Journal of Molecular Sciences, 23(8), Article 4075. https://doi.org/10.3390/ijms23084075
84. Kao, C., Lim, K. K., & Chen, E. S. (2025). Emerging epigenetic therapeutics and diagnostics for autism spectrum disorder. Current Issues in Molecular Biology, 47(7), Article 491. https://doi.org/10.3390/cimb47070491
85. Jean-Baptiste, Z., Pathak, Y., & Sneed, K. B. (2024). Nanomedicine-based drug delivery systems and the treatment of autism spectrum disorders: A review. Micro, 4(1), 132–141. https://doi.org/10.3390/micro4010010
86. Neumann, A., Walton, E., Alemany, S., Cecil, C., González, J. R., Jima, D. D., Lahti, C. P., Lin, S. L., Lucinski, S. J., Melton, S. J., Suderman, M., & Tiemeier, H. (2020). Association between DNA methylation and ADHD symptoms from birth to school age: a prospective meta-analysis. Translational Psychiatry, 10(1), Article 398. https://doi.org/10.1038/s41398-020-01082-x
87. Rucklidge, J. J., & Kaplan, B. J. (2014). Broad-spectrum micronutrient treatment for attention-deficit/hyperactivity disorder: rationale and evidence to date. CNS Drugs, 28(9), 775–785. https://doi.org/10.1007/s40263-014-0192-z
88. Pal, D., Sahu, P., Mishra, A. K., Hagelgans, A., & Sukocheva, O. (2023). Histone deacetylase inhibitors as cognitive enhancers and modifiers of mood and behavior. Current Drug Targets, 24(9), 728–750. https://doi.org/10.2174/1389450124666221207090108
89. Peixoto, L., & Abel, T. (2013). The role of histone acetylation in memory formation and cognitive impairments. Neuropsychopharmacology, 38(1), 62–76. https://doi.org/10.1038/npp.2012.154
90. Moretti, M., Valvassori, S. S., Varela, R. B., Ferreira, C. L., Rochi, N., Benedet, J., Bellettini, A. M., & Quevedo, J. (2011). Behavioral and neurochemical effects of sodium butyrate in an animal model of mania. Behavioural Pharmacology, 22(8), 766–772. https://doi.org/10.1097/FBP.0b013e32834d0b13
91. Basu, T., O’Riordan, K. J., Schoenike, B. A., Khan, N. N., Wallace, E. P., Rodriguez, G., Maganti, N., & Roopra, A. (2019). Histone deacetylase inhibitors restore normal hippocampal synaptic plasticity and seizure threshold in a mouse model of Tuberous Sclerosis Complex. Scientific Reports, 9(1), Article 5266. https://doi.org/10.1038/s41598-019-41549-w
92. Bekdash, R. A. (2023). Methyl donors, epigenetic alterations, and brain health: understanding the connection. International Journal of Molecular Sciences, 24(3), Article 2346. https://doi.org/10.3390/ijms24032346
93. Ghanizadeh, A., Sayyari, Z., & Mohammadi, M. R. (2013). Effect of methylphenidate and folic acid on ADHD symptoms and quality of life and aggression: A randomized double blind placebo controlled clinical trial. Iranian Journal of Psychiatry, 8(3), 108–112. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829457/
94. Hashizume, S., Nakano, M., Kubota, K., Sato, S., Himuro, N., Kobayashi, E., Washisaka, K., & Fujimiya, M. (2021). Mindfulness intervention improves cognitive function in older adults by enhancing the level of miRNA-29c in neuron-derived extracellular vesicles. Scientific Reports, 11(1), Article 21848. https://doi.org/10.1038/s41598-021-01306-0
95. Hollins, S. L., & Cairns, M. J. (2016). MicroRNA: Small RNA mediators of the brain’s genomic response to environmental stress. Progress in Neurobiology, 143, 61–81. https://doi.org/10.1016/j.pneurobio.2016.06.005
96. Nigg, J., Nikolas, M., & Burt, S. A. (2010). Measured gene-by-environment interaction in relation to attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 49(9), 863–873. https://doi.org/10.1016/j.jaac.2010.01.025
97. Kilgore, M., Miller, C. A., Fass, D. M., Hennig, K. M., Haggarty, S. J., Sweatt, J. D., & Rumbaugh, G. (2010). Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer’s disease. Neuropsychopharmacology, 35(4), 870–880. https://doi.org/10.1038/npp.2009.197
98. Zhang, Z. Y., & Schluesener, H. J. (2013). Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model. Journal of Neuropathology and Experimental Neurology, 72(3), 178–185. https://doi.org/10.1097/NEN.0b013e318283114a
99. Ricobaraza, A., Cuadrado-Tejedor, M., Marco, S., Pérez-Otaño, I., & García-Osta, A. (2012). Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus, 22(5), 1040–1050. https://doi.org/10.1002/hipo.20883
100. Benito, E., Urbanke, H., Ramachandran, B., Barth, J., Halder, R., Awasthi, A., Jain, G., Capece, V., Burkhardt, S., Mendez-Resendiz, M., Schütz, A. L., Prieto, C., Steenpass, L., Magel, L. K., Stefanatos, R. K., Ritter, C., Islam, S., Kaurani, L., Pradhan, R., & Fischer, A. (2015). HDAC inhibitor–dependent transcriptome and memory reinstatement in cognitive decline models. The Journal of Clinical Investigation, 125(9), 3572–3584. https://doi.org/10.1172/JCI79393
101. Levenson, J. M., Roth, T. L., Lubin, F. D., Miller, C. A., Huang, I. C., Desai, P., Malone, L. M., & Sweatt, J. D. (2006). Evidence that DNA (cytosine-5) methyltransferase regulates synaptic plasticity in the hippocampus. Journal of Biological Chemistry, 281(23), 15763–15773. https://doi.org/10.1074/jbc.M512468200
102. Pereira, P. A., Tomás, J. F., Queiroz, J. A., Figueiras, A. R., & Sousa, F. (2016). Recombinant pre-miR-29b for Alzheimer s disease therapeutics. Scientific Reports, 6(1), Article 19946. https://doi.org/10.1038/srep19946
103. Barros-Viegas, A. T., Carmona, V., Ferreiro, E., Guedes, J., Cardoso, A. M., Cunha, P., Pereira de Almeida, L., Resende de Oliveira, C., Pedro de Magalhães, J., Peça, J., & Cardoso, A. L. (2020). miRNA-31 improves cognition and abolishes amyloid-β pathology by targeting APP and BACE1 in an animal model of Alzheimer’s disease. Molecular Therapy – Nucleic Acids, 19, 1219–1236. https://doi.org/10.1016/j.omtn.2020.01.010
104. Su, D., Chai, Y., Yang, J., Wang, X., Liu, Y., Ma, J., Tang, X., Mishra, C., Chandra, S. R., Yue, W., & Ai, J. (2021). Lentivirus-carried microRNA-195 rescues memory deficits of Alzheimer’s disease transgenic mouse by attenuating the generation of amyloid plaques. Frontiers in Pharmacology, 12, Article 633805. https://doi.org/10.3389/fphar.2021.633805
105. Lin, E. Y., Hsu, S. X., Wu, B. H., Deng, Y. C., Wuli, W., Li, Y. S., Lee, J. H., Lin, S. Z., Harn, H. J., & Chiou, T. W. (2024). Engineered exosomes containing microRNA-29b-2 and targeting the somatostatin receptor reduce Presenilin 1 expression and decrease the β-amyloid accumulation in the brains of mice with Alzheimer’s disease. International Journal of Nanomedicine, 19, 4977–4994. https://doi.org/10.2147/IJN.S442876
106. Hassan, F. U., Rehman, M. S., Khan, M. S., Ali, M. A., Javed, A., Nawaz, A., & Yang, C. (2019). Curcumin as an alternative epigenetic modulator: Mechanism of action and potential effects. Frontiers in Genetics, 10, Article 514. https://doi.org/10.3389/fgene.2019.00514
107. Tarozzi, A., Angeloni, C., Malaguti, M., Morroni, F., Hrelia, S., & Hrelia, P. (2013). Sulforaphane as a potential protective phytochemical against neurodegenerative diseases. Oxidative Medicine and Cellular Longevity, 2013, Article 415078. https://doi.org/10.1155/2013/415078
108. Li, S. (2023). Benefits of physical exercise on Alzheimer’s disease: An epigenetic view. Ageing and Neurodegenerative Diseases, 3(6), Article 21. https://doi.org/10.20517/and.2023.21
109. da Silva Rodrigues, G., Noronha, N. Y., Noma, I. H. Y., de Lima, J. G. R., da Silva Sobrinho, A. C., de Souza Pinhel, M. A., Brunaldi, K., & Júnior, C. R. B. (2024). 14-week exercise training modifies the DNA methylation levels at gene sites in non-Alzheimer’s disease women aged 50 to 70 years. Experimental Gerontology, 186, Article 112362. https://doi.org/10.1016/j.exger.2024.112362
110. Hu, J., Huang, B., & Chen, K. (2024). The impact of physical exercise on neuroinflammation mechanism in Alzheimer’s disease. Frontiers in Aging Neuroscience, 16, Article 1444716. https://doi.org/10.3389/fnagi.2024.1444716
111. Kantor, B., Tagliafierro, L., Gu, J., Zamora, M. E., Ilich, E., Grenier, C., Huang, Z. Y., Murphy, S., & Chiba-Falek, O. (2018). Downregulation of SNCA expression by targeted editing of DNA methylation: A potential strategy for precision therapy in PD. Molecular Therapy, 26(11), 2638–2649. https://doi.org/10.1016/j.ymthe.2018.08.019
112. Suo, H., Wang, P., Tong, J., Cai, L., Liu, J., Huang, D., Huang, Y., & Huang, F. (2015). NRSF is an essential mediator for the neuroprotection of trichostatin A in the MPTP mouse model of Parkinson’s disease. Neuropharmacology, 99, 67–78. https://doi.org/10.1016/j.neuropharm.2015.07.013
113. St Laurent, R., O’Brien, L. M., & Ahmad, S. T. (2013). Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinson’s disease. Neuroscience, 246, 382–390. https://doi.org/10.1016/j.neuroscience.2013.04.037
114. Guo, T. T., Zhang, Z., Sun, Y., Zhu, R. Y., Wang, F. X., Ma, L. J., Shao, J., & Liu, H. D. (2023). Neuroprotective effects of sodium butyrate by restoring gut microbiota and inhibiting TLR4 signaling in mice with MPTP-induced Parkinson’s disease. Nutrients, 15(4), Article 930. https://doi.org/10.3390/nu15040930
115. Park, S. Y., & Kim, J. S. (2020). A short guide to histone deacetylases including recent progress on class II enzymes. Experimental & Molecular Medicine, 52(2), 204–212. https://doi.org/10.1038/s12276-020-0382-2
116. Gu, X., Zhang, H., Jiao, M., Han, B., Zhang, Z., Li, J., & Zhang, Q. (2022). Histone deacetylase 6 inhibitors with blood-brain barrier penetration as a potential strategy for CNS-disorders therapy. European Journal of Medicinal Chemistry, 229, Article 114090. https://doi.org/10.1016/j.ejmech.2021.114090
117. Miñones-Moyano, E., Porta, S., Escaramís, G., Rabionet, R., Iraola, S., Kagerbauer, B., Gila-Cebada, L., Ferrer, I., & Martí, E. (2011). MicroRNA profiling of Parkinson’s disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Human Molecular Genetics, 20(15), 3067–3078. https://doi.org/10.1093/hmg/ddr140
118. Kabaria, S., Choi, D. C., Chaudhuri, A. D., Mouradian, M. M., & Junn, E. (2015). Inhibition of miR-34b and miR-34c enhances α-synuclein expression in Parkinson’s disease. FEBS Letters, 589(3), 319–325. https://doi.org/10.1016/j.febslet.2014.12.014
119. Junn, E., Lee, K. W., Jeong, B. S., Chan, T. W., Im, J. Y., & Mouradian, M. M. (2009). Repression of α-synuclein expression and toxicity by microRNA-7. Proceedings of the National Academy of Sciences, 106(31), 13052–13057. https://doi.org/10.1073/pnas.0906277106
120. Doxakis, E. (2010). Post-transcriptional regulation of α-synuclein expression by miR-7 and miR-153. Journal of Biological Chemistry, 285(17), 12726–12734. https://doi.org/10.1074/jbc.M109.086553
121. Zhang, J., Zhao, M., Yan, R., Liu, J., Maddila, S., Junn, E., & Mouradian, M. M. (2021). MicroRNA-7 protects against neurodegeneration induced by α-synuclein preformed fibrils in the mouse brain. Neurotherapeutics, 18(4), 2529–2540. https://doi.org/10.1007/s13311-021-01119-z
122. Rodrigues-Costa, M., Fernandes, M. S. D. S., Jurema-Santos, G. C., Gonçalves, L. V. D. P., & Andrade-da-Costa, B. L. S. (2023). Nutrigenomics in Parkinson’s disease: Diversity of modulatory actions of polyphenols on epigenetic effects induced by toxins. Nutritional Neuroscience, 26(1), 72–84. https://doi.org/10.1080/1028415X.2021.2018244
123. Prasanth, M. I., Sivamaruthi, B. S., Cheong, C. S. Y., Verma, K., Tencomnao, T., Brimson, J. M., & Prasansuklab, A. (2024). Role of epigenetic modulation in neurodegenerative diseases: Implications of phytochemical interventions. Antioxidants, 13(5), 606. https://doi.org/10.3390/antiox13050606
124. Zhang, Y., Wang, Y., Dou, H., Wang, S., Qu, D., Peng, X., Li, X., Wang, Y., Qu, Y., & Yang, L. (2024). Caffeine improves mitochondrial dysfunction in the white matter of neonatal rats with hypoxia-ischemia through deacetylation: A proteomic analysis of lysine acetylation. Frontiers in Molecular Neuroscience, 17, 1394886. https://doi.org/10.3389/fnmol.2024.1394886
125. Shi, H., Deng, H. X., Gius, D., Schumacker, P. T., Surmeier, D. J., & Ma, Y. C. (2017). Sirt3 protects dopaminergic neurons from mitochondrial oxidative stress. Human Molecular Genetics, 26(10), 1915–1926. https://doi.org/10.1093/hmg/ddx100
126. Lee, S., Jeon, Y. M., Jo, M., & Kim, H. J. (2021). Overexpression of SIRT3 suppresses oxidative stress-induced neurotoxicity and mitochondrial dysfunction in dopaminergic neuronal cells. Experimental Neurobiology, 30(5), 341–355. https://doi.org/10.5607/en21021
127. Yan, Z. (2024). Targeting epigenetic enzymes for autism treatment. Trends in Pharmacological Sciences, 45(9), 764–767. https://doi.org/10.1016/j.tips.2024.06.009
128. Herrera, M. L., Paraíso-Luna, J., Bustos-Martínez, I., & Barco, Á. (2024). Targeting epigenetic dysregulation in autism spectrum disorders. Trends in Molecular Medicine, 30(11), 1028–1046. https://doi.org/10.1016/j.molmed.2024.06.004
129. Roth, G. V., Gengaro, I. R., & Qi, L. S. (2024). Precision epigenetic editing: Technological advances, enduring challenges, and therapeutic applications. Cell Chemical Biology. Advance online publication. https://doi.org/10.1016/j.chembiol.2024.07.007
130. Garrido-Torres, N., Guzmán-Torres, K., García-Cerro, S., Pinilla Bermúdez, G., Cruz-Baquero, C., Ochoa, H., García-González, D., Canal-Rivero, M., Crespo-Facorro, B., & Ruiz-Veguilla, M. (2024). miRNAs as biomarkers of autism spectrum disorder: A systematic review and meta-analysis. European Child & Adolescent Psychiatry, 33(9), 2957–2990. https://doi.org/10.1007/s00787-023-02138-3
131. Williams, L. A., & LaSalle, J. M. (2022). Future prospects for epigenetics in autism spectrum disorder. Molecular Diagnosis & Therapy, 26(6), 569–579. https://doi.org/10.1007/s40291-022-00608-z
132. Gholamalizadeh, H., Amiri-Shahri, M., Rasouli, F., Ansari, A., Baradaran Rahimi, V., & Reza Askari, V. (2024). DNA methylation in autism spectrum disorders: Biomarker or pharmacological target?. Brain Sciences, 14(8), 737. https://doi.org/10.3390/brainsci14080737
133. Peedicayil, J. (2022). The role of epigenetics in the pathogenesis and potential treatment of attention deficit hyperactivity disorder. Current Neuropharmacology, 20(9), 1642–1650. https://doi.org/10.2174/1570159X19666210920091036
134. Wang, D. Y., Kosowan, J., Samsom, J., Leung, L., Zhang, K. L., Li, Y. X., Xiong, Y., Jin, J., Petronis, A., Oh, G., & Wong, A. H. C. (2018). Inhibition of the G9a/GLP histone methyltransferase complex modulates anxiety-related behavior in mice. Acta Pharmacologica Sinica, 39(5), 866–874. https://doi.org/10.1038/aps.2017.190
135. Chao, Y., Qin, Y., Zou, X., Wang, X., Hu, C., Xia, F., & Zou, C. (2022). Promising therapeutic aspects in human genetic imprinting disorders. Clinical Epigenetics, 14(1), 146. https://doi.org/10.1186/s13148-022-01369-6
136. Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., Xiao, X., & Li, D. (2024). Epigenetics-targeted drugs: Current paradigms and future challenges. Signal Transduction and Targeted Therapy, 9(1), 332. https://doi.org/10.1038/s41392-024-02039-0
137. Skouras, P., Markouli, M., Strepkos, D., & Piperi, C. (2023). Advances on epigenetic drugs for pediatric brain tumors. Current Neuropharmacology, 21(7), 1519–1535. https://doi.org/10.2174/1570159X20666220922150456
138. Mirković, B., Chagraoui, A., Gerardin, P., & Cohen, D. (2020). Epigenetics and attention-deficit/hyperactivity disorder: New perspectives?. Frontiers in Psychiatry, 11, 579. https://doi.org/10.3389/fpsyt.2020.00579
139. Cecil, C. A. M., & Nigg, J. T. (2022). Epigenetics and ADHD: Reflections on current knowledge, research priorities and translational potential. Molecular Diagnosis & Therapy, 26(6), 581–606. https://doi.org/10.1007/s40291-022-00609-y
140. Caraci, F., Leggio, G. M., Drago, F., & Salomone, S. (2013). Epigenetic drugs for Alzheimer’s disease: hopes and challenges. British Journal of Clinical Pharmacology, 75(4), 1154–1155. https://doi.org/10.1111/j.1365-2125.2012.04443.x
141. Cummings, J., Lee, G., Apostolova, L., Zhong, K., Schade, A., & Ritter, A. (2025). Alzheimer’s disease drug development pipeline: 2025. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 11(1), e12534. https://doi.org/10.1002/trc2.12534
142. Ljubenkov, P. A., Edwards, L., Iaccarino, L., La Joie, R., Rojas, J. C., Koestler, M., Harris, B., Boeve, B. F., Borroni, B., van Swieten, J. C., Grossman, M., Pasquier, F., Frisoni, G. B., Mummery, C. J., Vandenberghe, R., Le Ber, I., Hannequin, D., McGinnis, S. M., Auriacombe, S., Onofrj, M., … Boxer, A. L. (2021). Effect of the histone deacetylase inhibitor FRM-0334 on progranulin levels in patients with progranulin gene haploinsufficiency: A randomized clinical trial. JAMA Network Open, 4(9), e2125584. https://doi.org/10.1001/jamanetworkopen.2021.25584
143. Wagner, F. F., Zhang, Y. L., Fass, D. M., Joseph, N., Gale, J. P., Weïwer, M., McCarren, P., Fisher, S. L., Kaya, T., Zhao, W. N., Reis, S. A., Hennig, K. M., Thomas, M., Lemercier, B. C., Lewis, M. C., Guan, J. S., Moyer, M. P., Scolnick, E., Haggarty, S. J., Tsai, L. H., … Holson, E. B. (2015). Kinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers. Chemical Science, 6(1), 804–815. https://doi.org/10.1039/C4SC02130D
144. Choi, M. A., Park, S. Y., Chae, H. Y., Song, Y., Sharma, C., & Seo, Y. H. (2019). Design, synthesis and biological evaluation of a series of CNS penetrant HDAC inhibitors structurally derived from amyloid-β probes. Scientific Reports, 9(1), 13187. https://doi.org/10.1038/s41598-019-49784-9
145. Singh, M. B., & Sartor, G. C. (2020). BET bromodomains as novel epigenetic targets for brain health and disease. Neuropharmacology, 181, 108306. https://doi.org/10.1016/j.neuropharm.2020.108306
146. Walgrave, H., Balusu, S., Snoeck, S., Vanden Eynden, E., Craessaerts, K., Thrupp, N., … & Salta, E. (2021). Restoring miR-132 expression rescues adult hippocampal neurogenesis and memory deficits in Alzheimer’s disease. Cell Stem Cell, 28(10), 1805–1821. https://doi.org/10.1016/j.stem.2021.05.001
147. Yu, N. K., Baek, S. H., & Kaang, B. K. (2011). DNA methylation-mediated control of learning and memory. Molecular Brain, 4(1), 5. https://doi.org/10.1186/1756-6606-4-5
148. Benito, E., Ramachandran, B., Schroeder, H., Schmidt, G., Urbanke, H., Burkhardt, S., … & Fischer, A. (2017). The BET/BRD inhibitor JQ1 improves brain plasticity in WT and APP mice. Translational Psychiatry, 7(9), e1239–e1239. https://doi.org/10.1038/tp.2017.202
149. Rainey-Smith, S. R., Brown, B. M., Sohrabi, H. R., Shah, T., Goozee, K. G., Gupta, V. B., & Martins, R. N. (2016). Curcumin and cognition: A randomised, placebo-controlled, double-blind study of community-dwelling older adults. British Journal of Nutrition, 115(12), 2106–2113. https://doi.org/10.1017/S000711451600120X
150. Turner, R. S., Thomas, R. G., Craft, S., van Dyck, C. H., Mintzer, J., Reynolds, B. A., Brewer, J. B., Rissman, R. A., Raman, R., Aisen, P. S., & Alzheimer’s Disease Cooperative Study. (2015). A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology, 85(16), 1383–1391. https://doi.org/10.1212/WNL.0000000000002035
151. Song, H., Chen, J., Huang, J., Sun, P., Liu, Y., Xu, L., Wei, C., Mu, X., Lu, X., Wang, W., Zhang, N., Shang, M., Mo, M., Zhang, W., Zhao, H., & Han, F. (2023). Epigenetic modification in Parkinson’s disease. Frontiers in Cell and Developmental Biology, 11, 1123621. https://doi.org/10.3389/fcell.2023.1123621
152. Bennett, C. F., Kordasiewicz, H. B., & Cleveland, D. W. (2021). Antisense drugs make sense for neurological diseases. Annual Review of Pharmacology and Toxicology, 61, 831–852. https://doi.org/10.1146/annurev-pharmtox-010919-023738
153. Cole, T. A., Zhao, H., Collier, T. J., Sandoval, I., Sortwell, C. E., Steece-Collier, K., Daley, B. F., Booms, A., Lipton, J., Welch, M., Berman, M., Jandreski, L., Graham, D., Weihofen, A., Celano, S., Schulz, E., Cole-Strauss, A., Luna, E., Quach, D., Mohan, A., … Paumier, K. L. (2021). α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease. JCI Insight, 6(5), e135633. https://doi.org/10.1172/jci.insight.135633
154. Magalhães, P., & Lashuel, H. A. (2022). Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies. NPJ Parkinson’s Disease, 8(1), 93. https://doi.org/10.1038/s41531-022-00357-0
155. Suvarna, V., Deshmukh, K., & Murahari, M. (2022). miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease. Frontiers in Pharmacology, 13, 1034072. https://doi.org/10.3389/fphar.2022.1034072
156. Feehley, T., O’Donnell, C. W., Mendlein, J., Karande, M., & McCauley, T. (2023). Drugging the epigenome in the age of precision medicine. Clinical Epigenetics, 15(1), 6. https://doi.org/10.1186/s13148-022-01419-z
157. Yuan, L., Xiong, Y., Zhang, Y., Gu, S., & Lei, Y. (2025). Epigenome editing based treatment: Progresses and challenges. Molecular Therapy, S1525-0016(25)00721-X. Advance online publication. https://doi.org/10.1016/j.ymthe.2025.08.047
158. Boudadi, E., Stower, H., Halsall, J. A., Rutledge, C. E., Leeb, M., Wutz, A., O’Neill, L. P., Nightingale, K. P., & Turner, B. M. (2013). The histone deacetylase inhibitor sodium valproate causes limited transcriptional change in mouse embryonic stem cells but selectively overrides Polycomb-mediated Hoxb silencing. Epigenetics & Chromatin, 6(1), 11. https://doi.org/10.1186/1756-8935-6-11
159. Rada-Iglesias, A., Enroth, S., Ameur, A., Koch, C. M., Clelland, G. K., Respuela-Alonso, P., Hurd, D., Birney, E., & Wadelius, C. (2007). Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes. Genome Research, 17(6), 708–719. https://doi.org/10.1101/gr.5746307
160. Ware, C. B., Wang, L., Mecham, B. H., Shen, L., Nelson, A. M., Bar, M., Lamba, D. A., Dauphin, D. S., Buckingham, B., Askari, B., Lim, R., Tewari, M., Gartler, S. M., Issa, J. P., Pavlidis, P., Duan, Z., & Blau, C. A. (2009). Histone deacetylase inhibition elicits an evolutionarily conserved self-renewal program in embryonic stem cells. Cell Stem Cell, 4(4), 359–369. https://doi.org/10.1016/j.stem.2009.03.001
161. Zocher, S. (2024). Targeting neuronal epigenomes for brain rejuvenation. The EMBO Journal, 43(16), 3312–3326. https://doi.org/10.1038/s44318-024-00148-8
162. Ghosh, P., & Saadat, A. (2023). Neurodegeneration and epigenetics: A review. Neurología (English Edition), 38(6), e62–e68. https://doi.org/10.1016/j.nrleng.2023.05.001
163. Roth, T. L., Lubin, F. D., Funk, A. J., & Sweatt, J. D. (2009). Lasting epigenetic influence of early-life adversity on the BDNF gene. Biological Psychiatry, 65(9), 760–769. https://doi.org/10.1016/j.biopsych.2008.11.028
164. Kundakovic, M., & Champagne, F. A. (2015). Early-life experience, epigenetics, and the developing brain. Neuropsychopharmacology, 40(1), 141–153. https://doi.org/10.1038/npp.2014.140
165. Burns, S. B., Szyszkowicz, J. K., Luheshi, G. N., Lutz, P. E., & Turecki, G. (2018). Plasticity of the epigenome during early-life stress. Seminars in Cell & Developmental Biology, 77, 115–132. https://doi.org/10.1016/j.semcdb.2017.09.033
166. Roberti, A., Valdes, A. F., Torrecillas, R., Fraga, M. F., & Fernandez, A. F. (2019). Epigenetics in cancer therapy and nanomedicine. Clinical Epigenetics, 11(1), Article 81. https://doi.org/10.1186/s13148-019-0675-4
167. Li, G., Tian, Y., & Zhu, W. G. (2020). The roles of histone deacetylases and their inhibitors in cancer therapy. Frontiers in Cell and Developmental Biology, 8, Article 576946. https://doi.org/10.3389/fcell.2020.576946
168. Soshnev, A. A., Josefowicz, S. Z., & Allis, C. D. (2016). Greater than the sum of parts: Complexity of the dynamic epigenome. Molecular Cell, 62(5), 681–694. https://doi.org/10.1016/j.molcel.2016.05.004
169. Ganesan, A., Arimondo, P. B., Rots, M. G., Jeronimo, C., & Berdasco, M. (2019). The timeline of epigenetic drug discovery: From reality to dreams. Clinical Epigenetics, 11(1), Article 174. https://doi.org/10.1186/s13148-019-0776-0
170. Rodríguez-Paredes, M., & Esteller, M. (2011). Cancer epigenetics reaches mainstream oncology. Nature Medicine, 17(3), 330–339. https://doi.org/10.1038/nm.2305
171. Ren, L., Yang, Y., Li, W., Yang, H., Zhang, Y., Ge, B., Zhang, S., Du, G., & Wang, J. (2023). Recent advances in epigenetic anticancer therapeutics and future perspectives. Frontiers in Genetics, 13, Article 1085391. https://doi.org/10.3389/fgene.2022.1085391
172. Sahafnejad, Z., Ramazi, S., & Allahverdi, A. (2023). An update of epigenetic drugs for the treatment of cancers and brain diseases: A comprehensive review. Genes, 14(4), Article 873. https://doi.org/10.3390/genes14040873
173. Zhang, Z., Wang, G., Li, Y., Lei, D., Xiang, J., Ouyang, L., … & Yang, J. (2022). Recent progress in DNA methyltransferase inhibitors as anticancer agents. Frontiers in Pharmacology, 13, Article 1072651. https://doi.org/10.3389/fphar.2022.1072651
174. Abballe, L., & Miele, E. (2021). Epigenetic modulators for brain cancer stem cells: Implications for anticancer treatment. World Journal of Stem Cells, 13(7), 670–695. https://doi.org/10.4252/wjsc.v13.i7.670
175. Ihezie, S. A., Mathew, I. E., McBride, D. W., Dienel, A., Blackburn, S. L., & Thankamani Pandit, P. K. (2021). Epigenetics in blood–brain barrier disruption. Fluids and Barriers of the CNS, 18(1), Article 17. https://doi.org/10.1186/s12987-021-00251-0
176. Vasanthakumar, A., Davis, J. W., Idler, K., Waring, J. F., Asque, E., Riley-Gillis, B., … Alzheimer’s Disease Neuroimaging Initiative. (2020). Harnessing peripheral DNA methylation differences in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) to reveal novel biomarkers of disease. Clinical Epigenetics, 12(1), Article 84. https://doi.org/10.1186/s13148-020-00876-0
177. Berson, A., Nativio, R., Berger, S. L., & Bonini, N. M. (2018). Epigenetic regulation in neurodegenerative diseases. Trends in Neurosciences, 41(9), 587–598. https://doi.org/10.1016/j.tins.2018.05.005
178. Huo, Z., Zhu, Y., Yu, L., Yang, J., De Jager, P., Bennett, D. A., & Zhao, J. (2019). DNA methylation variability in Alzheimer’s disease. Neurobiology of Aging, 76, 35–44. https://doi.org/10.1016/j.neurobiolaging.2018.12.006
179. Sasaki-Honda, M., Akatsuka, K., & Sawai, T. (2023). Is epigenome editing non-inheritable? Implications for ethics and the regulation of human applications. Stem Cell Reports, 18(11), 2005–2009. https://doi.org/10.1016/j.stemcr.2023.09.006
180. Roy, M. C., Dupras, C., & Ravitsky, V. (2017). The epigenetic effects of assisted reproductive technologies: Ethical considerations. Journal of Developmental Origins of Health and Disease, 8(4), 436–442. https://doi.org/10.1017/S204017441700016X
181. Nilsson, E. E., Sadler-Riggleman, I., & Skinner, M. K. (2018). Environmentally induced epigenetic transgenerational inheritance of disease. Environmental Epigenetics, 4(2), Article dvy016. https://doi.org/10.1093/eep/dvy016
182. Park, H., Shin, J., Kim, Y., Saito, T., Saido, T. C., & Kim, J. (2022). CRISPR/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer’s disease. Translational Neurodegeneration, 11(1), Article 41. https://doi.org/10.1186/s40035-022-00315-4
183. Pulecio, J., Verma, N., Mejía-Ramírez, E., Huangfu, D., & Raya, A. (2017). CRISPR/Cas9-based engineering of the epigenome. Cell Stem Cell, 21(4), 431–447. https://doi.org/10.1016/j.stem.2017.09.006
184. Bagheri, A., Habibzadeh, P., Razavipour, S. F., Volmar, C. H., Chee, N. T., Brothers, S. P., … & Faghihi, M. A. (2019). HDAC inhibitors induce BDNF expression and promote neurite outgrowth in human neural progenitor cells-derived neurons. International Journal of Molecular Sciences, 20(5), Article 1109. https://doi.org/10.3390/ijms20051109
185. Sada, N., Fujita, Y., Mizuta, N., Ueno, M., Furukawa, T., & Yamashita, T. (2020). Inhibition of HDAC increases BDNF expression and promotes neuronal rewiring and functional recovery after brain injury. Cell Death & Disease, 11(8), Article 655. https://doi.org/10.1038/s41419-020-02859-w
186. Ricciardi, N. R., Modarresi, F., Lohse, I., Andrade, N. S., Newman, I. R., Brown, J. M., … & Volmar, C. H. (2023). Investigating the synergistic potential of low-dose HDAC3 inhibition and radiotherapy in Alzheimer’s disease models. Molecular Neurobiology, 60(8), 4811–4827. https://doi.org/10.1007/s12035-023-03362-x
187. O’Riordan, K. J., Collins, M. K., Moloney, G. M., Knox, E. G., Aburto, M. R., Fülling, C., … & Cryan, J. F. (2022). Short chain fatty acids: Microbial metabolites for gut-brain axis signalling. Molecular and Cellular Endocrinology, 546, Article 111572. https://doi.org/10.1016/j.mce.2021.111572
188. Krautkramer, K. A., Fan, J., & Bäckhed, F. (2021). Gut microbial metabolites as multi-kingdom intermediates. Nature Reviews Microbiology, 19(2), 77–94. https://doi.org/10.1038/s41579-020-0438-4
189. Cao, Q., Shen, M., Li, R., Liu, Y., Zeng, Z., Zhou, J., … & Zhang, G. (2025). Elucidating the specific mechanisms of the gut-brain axis: The short-chain fatty acids-microglia pathway. Journal of Neuroinflammation, 22(1), Article 133. https://doi.org/10.1186/s12974-025-03123-x
190. Nguyen, T. M., Kim, N., Kim, D. H., Le, H. L., Piran, M. J., Um, S. J., & Kim, J. H. (2021). Deep learning for human disease detection, subtype classification, and treatment response prediction using epigenomic data. Biomedicines, 9(11), Article 1733. https://doi.org/10.3390/biomedicines9111733
191. Yuan, T., Edelmann, D., Fan, Z., Alwers, E., Kather, J. N., Brenner, H., & Hoffmeister, M. (2023). Machine learning in the identification of prognostic DNA methylation biomarkers among patients with cancer: A systematic review of epigenome-wide studies. Artificial Intelligence in Medicine, 143, Article 102589. https://doi.org/10.1016/j.artmed.2023.102589
192. Rauschert, S., Raubenheimer, K., Melton, P. E., & Huang, R. C. (2020). Machine learning and clinical epigenetics: A review of challenges for diagnosis and classification. Clinical Epigenetics, 12(1), Article 51. https://doi.org/10.1186/s13148-020-00842-4